Your browser doesn't support javascript.
loading
Bleeding tendency and ascorbic acid requirements: systematic review and meta-analysis of clinical trials.
Hujoel, Philippe P; Kato, Tomotaka; Hujoel, Isabel A; Hujoel, Margaux L A.
Afiliação
  • Hujoel PP; Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
  • Kato T; Department of Oral Health Sciences, School of Dentistry, University of Washington, Seattle, Washington, USA.
  • Hujoel IA; Department of Oral Health Sciences, School of Dentistry, University of Washington, Seattle, Washington, USA.
  • Hujoel MLA; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Nutr Rev ; 79(9): 964-975, 2021 08 09.
Article em En | MEDLINE | ID: mdl-33517432
ABSTRACT
CONTEXT The World Health Organization set the recommended daily vitamin C intake, henceforth referred to as ascorbic acid (AA), on the basis of scurvy prevention. Double-blind AA depletion-repletion studies suggest that this recommended AA dose may be too low to prevent microvascular fragility.

OBJECTIVES:

(1) To conduct a systematic review and meta-analysis of controlled clinical trials on whether AA supplementation leads to a reduced gingival bleeding tendency, a manifestation of microvascular fragility; and (2) to relate AA plasma levels to retinal hemorrhaging, another manifestation of microvascular fragility. DATA SOURCES Data were reviewed from 15 trials conducted in 6 countries with 1140 predominantly healthy participants with measures of gingival bleeding tendency, and from the National Health and Nutrition Examination Survey (NHANES) III of 8210 US residents with measures of retinal hemorrhaging.

RESULTS:

In clinical trials, AA supplementation reduced gingival bleeding tendency when estimated baseline AA plasma levels were < 28 µmol/L (standardized mean difference [SMD], -0.83; 95%CI, -1.16 to -0.49; P < 0.002). Supplementation with AA did not unequivocally reduce gingival bleeding tendency when baseline estimated AA plasma levels were >48 µmol/L or unknown (respective standardized mean differences -0.23, 95%CI, -0.45 to -0.01, P < 0.05; and -0.56; 95%CI -1.19 to 0.06, P < 0.08). In NHANES III, prevalence of both retinal hemorrhaging and gingival bleeding tendency increased when AA plasma levels were within the range that protects against scurvy (11-28 µmol/L; respective prevalence ratios adjusted for age and sex 1.47; 95%CI 1.22-1.77; and 1.64; 95%CI 1.32-2.03; P < 0.001 for both).

CONCLUSION:

Consistent evidence from controlled clinical trials indicates that setting human AA requirements based on scurvy prevention leads to AA plasma levels that may be too low to prevent an increased gingival bleeding tendency. Gingival bleeding tendency and retinal hemorrhaging coincide with low AA plasma levels and thus may be reflective of a systemic microvascular pathology that is reversible with an increased daily AA intake.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácido Ascórbico / Gengiva / Hemorragia Tipo de estudo: Clinical_trials / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácido Ascórbico / Gengiva / Hemorragia Tipo de estudo: Clinical_trials / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article